suppresor
cytokin
signal
soc
protein
regul
cytokin
respons
control
immun
balanc
sever
studi
confirm
increas
asthmat
patient
express
correl
diseas
sever
object
studi
evalu
deliv
short
interf
rna
sirna
intranas
lung
could
good
therapeut
approach
asthma
chronic
mous
model
result
show
intranas
treatment
led
improv
eosinophil
count
normal
hyperrespons
methacholin
concomitantli
treatment
result
improv
mucu
secret
reduct
lung
collagen
promin
featur
airway
remodel
mechan
impli
jakstat
rhoarhokinas
signal
pathway
found
decreas
phosphoryl
statu
regul
rhoarhokinas
protein
express
result
might
lead
new
therapi
treatment
chronic
asthma
asthma
disord
conduct
airway
lead
variabl
airflow
obstruct
associ
airway
hyperrespons
character
inflammatori
cell
infiltr
mainli
eosinophil
lymphocyt
revers
bronchoconstrict
diseas
becom
sever
airway
acquir
alter
repair
respons
structur
chang
caus
remodel
due
secret
factor
cytokin
induc
mucou
cell
metaplasia
angiogenesi
subepitheli
fibrosi
cytokin
one
main
solubl
molecul
particip
initi
perpetu
execut
resolut
inflammatori
respons
therefor
tight
control
cytokin
product
function
requir
prevent
imbal
magnitud
durat
remiss
immun
respons
soc
protein
recogn
import
mechan
neg
regul
sever
cytokin
pathway
recent
studi
reveal
soc
protein
play
addit
role
mani
immunolog
process
asthma
cytokin
profil
asthma
typifi
interleukin
il
typic
cytokin
cytokin
bind
membran
receptor
activ
complex
signal
transduct
pathway
soc
famili
molecul
suppress
jakstat
signal
pathway
regul
th
cell
differenti
inhibitor
rel
specif
addit
inhibit
signal
pathway
raserk
affect
cell
prolifer
surviv
differenti
cell
contain
high
level
protein
group
recent
describ
increas
express
eosinophil
asthmat
patient
patient
asthma
atop
dermat
express
level
transcript
cell
close
correl
serum
ige
level
diseas
sever
previous
transgen
express
cell
result
increas
cell
product
airway
eosinophilia
airway
hyperrespons
ahr
murin
model
ovaallerg
asthma
fact
cell
treatment
demonstr
suppress
develop
allerg
inflamm
anoth
murin
model
asthma
gene
silenc
rna
interfer
express
target
gene
silenc
posttranscript
manner
arisen
potenti
treatment
mani
diseas
intranas
administr
nake
sirna
open
new
possibl
drug
deliveri
respiratori
therapi
therefor
develop
therapeut
approach
murin
model
chronic
asthma
deliv
intranas
experiment
procedur
carri
strict
accord
intern
nation
real
decreto
guidelin
approv
anim
research
ethic
committe
protocol
perform
condit
minim
anim
suffer
male
aj
mice
specif
pathogenfre
week
old
purchas
harlan
iberica
total
anim
includ
studi
mice
assign
experiment
group
salin
solut
group
ss
n
ovalbuminsensit
group
ova
n
ovalbuminsensit
nontarget
sirnatr
group
ova
sint
n
ovalbuminsensit
sirnatr
group
ova
n
ovalbumin
ova
grade
v
purchas
sigmaaldrich
mo
usa
antibodi
ser
bactin
obtain
cell
signal
technolog
usa
antimous
acquir
sta
cruz
biotech
ca
usa
antimous
rhoa
purchas
cytoskeleton
co
usa
flow
cytometri
antibodi
antimous
pe
pe
fitc
purchas
bd
ny
usa
mice
sensit
day
intraperiton
inject
mg
ova
grade
v
sigma
aldrich
mo
usa
mg
al
oh
pb
mice
immun
five
week
four
time
per
week
start
day
finish
day
place
small
box
later
anesthet
inhal
isofluoran
foran
abbot
il
usa
immun
ml
ova
mgml
salin
solut
ss
intranas
hour
last
ova
administr
mice
sacrif
follow
protocol
detail
miyamoto
et
al
accel
sirna
smartpool
duplex
predesign
mous
purchas
dharmacon
il
usa
sirna
sequenc
specif
mous
sens
antisens
sens
antisens
sens
antisens
sens
antisens
select
synthes
anneal
manufactur
addit
nontarget
sirna
scrambl
duplex
dharmacon
use
sens
antisens
nontarget
sirna
dissolv
rnasefre
water
given
intranas
volum
ml
previous
anim
lightli
anesthes
use
isofluoran
first
sensit
ova
total
dose
sirna
administ
everi
day
determin
effect
dose
differ
concentr
test
mm
mice
chronic
asthma
optim
sirna
concentr
select
mm
accel
cyclophilin
b
sirna
rhodamin
label
purchas
dharmacon
instil
intranas
mice
twentyfour
hour
sirna
instil
frozen
lung
section
observ
confoc
microscopi
leyca
microsystem
weztlar
germani
excit
wavelength
nm
mice
airway
respons
assess
anim
group
day
anim
sacrif
four
individu
whole
bodi
plethysmographi
chamber
obtain
buxco
use
describ
previous
enhanc
paus
penh
paramet
correl
measur
airway
resist
use
perform
analysi
vivo
ct
imag
perform
nanopetct
smallanim
imag
system
bioscan
washington
dc
equip
microfocu
xray
sourc
highresolut
radiationimag
devic
featur
pixel
photodiod
array
pixel
pitch
mm
mice
intraperiton
anesthet
ketaminexylacin
mg
per
kg
bodi
weight
posit
thermoregul
mous
bed
ophthalm
gel
eye
prevent
retin
dri
scan
paramet
use
ct
measur
projectionsrot
kv
peak
current
detector
pixel
size
mm
acquisit
reconstruct
perform
use
proprietari
nuclin
softwar
mediso
budapest
hungari
effect
induc
intranas
challeng
ovalbumin
observ
hounsfield
unit
densiti
chang
volum
chang
quantifi
manual
use
osirix
softwar
pixmeo
switzerland
appropri
ct
imag
preset
lung
window
set
center
hu
width
tail
vein
inject
nmol
prosens
agent
perkin
elmer
us
resuspend
ml
salin
perform
mice
day
hour
final
intranas
administr
ova
applic
mice
anesthet
isofluoran
twenti
hour
fluoresc
agent
deliveri
mice
imag
use
fmt
fluoresc
tomographi
system
perkin
elmer
depil
minim
interfer
fluoresc
signal
immedi
imag
mice
anesthetis
use
intraperiton
inject
ketamin
xylazin
ml
per
g
anim
posit
care
fmt
chamber
ophthalm
gel
eye
prevent
retin
dri
result
data
reconstruct
region
interest
roi
defin
within
chest
area
use
truequant
softwar
obtain
quantif
threshold
appli
anim
twentyfour
hour
last
administr
antigen
mice
anesthet
lung
lavag
perform
time
ml
steril
pb
cell
obtain
count
neubauer
chamber
use
cytometr
analysi
fac
canto
ii
cytomet
bd
ny
usa
right
lung
mous
extract
anim
termin
anaesthesia
lung
immers
paraformaldehyd
fivemicromet
section
stain
h
e
assess
gener
morpholog
mucoussecret
goblet
cell
visual
period
acidschiff
pa
masson
trichrom
stain
use
evalu
subepitheli
fibrosi
cell
infiltr
tissu
specimen
assess
count
number
cell
semiautomat
method
imag
j
softwar
use
imag
analysi
analys
perform
blind
fashion
slide
present
random
order
examin
protein
extract
mice
lung
mg
total
protein
resolv
sdspage
probe
specif
ab
appropri
dilut
rhoa
bactin
chemiluminesc
protein
band
detect
use
ecl
detect
system
amersham
bioscienc
ge
healthcar
buckinghamshir
uk
accord
manufactur
protocol
mice
lung
homogen
previous
total
rna
isol
follow
trizol
reagent
protocol
invitrogen
ca
usa
rna
measur
spectrophotometri
mg
rna
reversetranscrib
cdna
use
highcapac
cdna
revers
transcript
kit
appli
biosystem
warrington
uk
quantit
realtim
pcr
perform
realtim
pcr
system
appli
biosystem
taqman
gene
express
master
mix
taqman
gene
express
assay
probe
ifnc
obtain
appli
biosystem
use
qrtpcr
determin
mrna
level
messeng
rna
calcul
sampl
use
cycl
threshold
c
valu
rel
gene
express
calcul
follow
ddc
dc
target
gene
actin
total
rna
isol
lung
use
rneasi
mini
kit
qiagen
hilden
germani
accord
manufactur
protocol
integr
quantif
total
rna
extract
assess
agil
bioanalyz
agil
technolog
ca
usa
unqualifi
sampl
reject
total
mg
purifi
rna
sampl
submit
gene
express
depart
complutens
univers
madrid
spain
total
sampl
analyz
ova
group
ova
sint
group
ova
group
ss
group
follow
appropri
protocol
procedur
qualiti
control
label
fragment
total
rna
biotinlabel
crna
sampl
hybrid
genechip
mirna
array
affimetrix
ca
usa
accord
manufactur
protocol
microarray
normal
process
determin
softwar
genechip
express
consol
affimetrix
data
standard
use
rmadabg
algorithm
function
analysi
carri
use
babelom
suit
http
www
babelomicsorg
differenti
gene
express
conduct
use
limma
packag
bioconductor
http
www
bioconductororg
account
multipl
test
effect
p
valu
correct
use
fals
discoveri
rate
differenti
detect
signal
accept
true
ratio
p
valu
less
result
final
given
term
fold
induct
determin
total
serum
ige
ovaspecif
ige
time
sacrific
blood
sampl
collect
cardiac
punctur
sera
store
use
total
serum
ige
ovaspecif
ige
measur
elisa
bd
biosciencesbd
pharmingen
nj
usa
firstli
perform
assay
determin
whether
nake
sirna
deliv
intranas
reach
lung
intact
degrad
rnase
lung
airway
instil
control
sirna
label
mm
fluorophor
rhodamin
airway
red
fluoresc
observ
confoc
microscopi
respons
nm
laser
beam
shown
figur
strong
red
fluoresc
local
lung
predominantli
peribronchi
epitheli
cell
either
hour
administr
fluoresc
observ
lung
control
group
set
studi
gene
express
encod
protein
lung
tissu
quantit
pcr
western
blot
therapi
plot
figur
show
gene
express
inhibit
lung
mice
receiv
therapi
ova
sint
vs
ova
immunoblot
analysi
confirm
result
fig
thu
group
treat
control
group
show
similar
protein
express
vs
arbitrari
unit
ie
strong
inhibit
rel
ova
ova
sint
group
respect
fig
assess
whether
deliveri
caus
alter
import
regul
belong
famili
new
measur
mrna
rel
level
reveal
chang
gene
express
see
figur
final
analyz
whether
silenc
therapi
affect
organ
quantit
pcr
perform
liver
spleen
mice
observ
treatment
alter
gene
express
test
organ
see
figur
airway
function
assess
use
whole
bodi
plethysmographi
hour
sacrific
ova
ova
sinttreat
mice
develop
significantli
enhanc
respons
methacholin
compar
salin
anim
fig
expect
sirnatr
mice
display
significantli
inhibitori
respons
cholinerg
stimul
differ
methacholin
dose
mgml
compar
asthmat
group
therefor
therapi
protect
methacholineinduc
ahr
typic
microct
imag
group
illustr
figur
increas
densiti
unit
anim
lung
ova
ova
sinttreat
group
hu
observ
imag
fig
panel
mice
treat
reduct
hu
obtain
hu
although
differ
reach
statist
signific
fig
panel
fmt
imag
multipl
anim
fig
display
similar
pattern
extens
fluoresc
signal
ova
ova
sinttreat
mice
similarli
control
cellular
airway
inflamm
pivot
event
ovainduc
airway
sensit
expect
treatment
produc
chang
total
number
composit
cell
bal
figur
show
therapi
absolut
number
bal
cell
significantli
decreas
comparison
ova
group
cell
versu
cell
flow
cytometri
use
evalu
percentag
differ
cell
subpopul
bal
shown
fig
treatment
alter
cellular
profil
result
signific
reduct
eosinophil
decreas
bal
fluid
find
signific
chang
leukocyt
popul
measur
neutrophil
lymphocyt
b
result
indic
administr
lung
modul
allergeninduc
balf
eosinophilia
treatment
result
reduct
inflammatori
infiltr
perivascular
peribronchi
region
mice
lung
fig
compar
ova
ova
sint
group
fig
c
infiltr
quantifi
semiautomat
analysi
result
present
figur
excess
mucou
secret
hyperplas
goblet
cell
also
characterist
featur
asthmat
airway
determin
extent
mucou
cell
metaplasia
follow
knockdown
modifi
paraffinembed
section
lung
stain
pa
stain
mucousproduc
goblet
cell
asthmat
repres
exampl
sever
mice
display
similar
result
band
quantifi
densitometri
ss
group
mean
n
ova
group
mean
n
ova
sinttreat
group
mean
n
ova
group
mean
n
group
airway
mice
chronic
asthma
well
treat
nontarget
sirna
fig
h
increas
pasposit
cell
observ
bronchial
epithelium
compar
salin
control
fig
posit
cell
almost
disappear
ova
mice
receiv
therapi
therefor
display
similar
pattern
observ
airway
mice
salin
group
fig
increas
collagen
deposit
hallmark
airway
remodel
due
prolong
inflamm
chronic
asthma
connect
tissu
examin
lung
section
stain
masson
trichrom
salin
mice
present
thin
uniform
layer
matrix
peribronchi
subepitheli
region
fig
wherea
chronic
asthmat
mice
detect
increas
matrix
thick
subepitheli
layer
airway
well
perivascular
region
fig
shown
increas
extent
collagen
deposit
intens
stain
similar
result
obtain
ova
mice
treat
nontarget
sirna
fig
asthmat
mice
treat
intranas
found
matrix
deposit
consist
abrog
region
fig
also
tri
ascertain
whether
treatment
might
alter
humor
immun
respons
seen
tabl
determin
serum
ige
reveal
treatment
total
ige
level
alter
compar
mice
chronic
asthma
ova
group
specif
measur
ova
indic
respons
ag
modifi
silenc
group
group
howev
slight
reduct
ovaspecif
ige
level
observ
assess
effect
silenc
lung
cytokin
level
result
indic
cytokin
increas
mice
chronicinduc
asthma
figur
b
c
compar
salin
mice
treatment
deliv
mrna
level
significantli
lower
ova
group
fig
b
c
also
found
elev
infc
mrna
express
level
asthmat
mice
group
signific
chang
found
level
infc
silenc
figur
also
evalu
regulatori
axi
gene
express
mark
increas
mrna
express
compar
ova
mice
achiev
mice
downregul
shown
figur
corrobor
increas
product
downregul
bal
fluid
data
shown
contrast
mrna
level
augment
ova
mice
inhibit
sirnatr
mice
fig
gener
mice
treat
nontarget
sirna
display
similar
cytokin
express
profil
ova
mice
although
nonspecif
sirna
treatment
seem
affect
mrna
rel
level
alter
reach
signific
differ
thu
analysi
express
level
sever
cytokin
studi
group
show
predomin
mediat
downregul
silenc
contrast
upregul
local
inflammatori
process
airway
jakstat
pathway
activ
chronic
asthma
ascertain
phosphoryl
state
deliveri
perform
western
blot
analysi
phosphoryl
induc
ova
ova
sinttreat
mice
mice
treat
show
reduct
statu
fig
figur
summar
protein
express
quantifi
densitometri
normal
level
rhoarho
kinas
pathway
directli
implic
asthma
promot
bronchoconstrict
airway
remodel
airway
inflamm
model
rhoa
protein
express
increas
chronic
asthmat
mice
ova
ova
sint
group
wherea
mice
treatment
found
less
protein
express
intermedi
rhoa
fig
protein
band
quantifi
densitometri
result
plot
figur
respect
mirna
recogn
key
regulatori
element
gene
express
determin
mirna
modifi
express
follow
therapi
asthma
mous
model
use
microarray
analysi
tabl
display
mirna
affect
therapi
comparison
ova
ova
sint
versu
ova
group
show
total
mirna
downregul
asthmat
treat
group
first
column
mirna
augment
due
treatment
second
column
present
studi
provid
new
insight
asthma
therapi
develop
success
test
intranas
deliv
sirna
therapi
ovainduc
mous
model
chronic
asthma
transient
knockdown
nake
sirna
chronic
asthmat
mice
led
decreas
lung
eosinophilia
well
signific
reduct
ahr
mucou
airway
therefor
improv
chronic
remodel
inhibit
airway
alter
measur
reduct
cellular
infiltr
globet
cell
hyperplasia
matrix
deposit
histolog
analysi
airway
silenc
reveal
diminish
perialveolar
peribronchi
cellular
infiltr
conserv
structur
airway
epithelium
model
asthma
treatment
produc
also
decreas
express
indic
therapi
directli
regul
differenti
rate
well
known
activ
particip
promot
eosinophil
infiltr
airway
surpris
silenc
therapi
gene
express
lung
mice
reduc
correl
decreas
eosinophil
number
chronic
ova
challeng
mrna
level
dramat
upregul
lung
well
splenocyt
cultur
stimul
ova
antigen
see
figur
airway
capac
induc
ige
isotyp
switch
increas
mucou
product
airway
epitheli
cell
moreov
one
key
cytokin
regul
differenti
phenotyp
similarli
found
high
level
airway
asthmat
mice
il
tradit
relat
increas
ahr
mani
effort
find
inhibitor
cytokin
outcom
yet
fulfil
expect
kasaian
et
al
recent
publish
therapi
dual
antagonist
reduc
lung
inflamm
ahr
ige
product
ovainduc
asthma
murin
ova
sinttreat
group
mean
n
ova
group
mean
n
signific
differ
express
level
obtain
ova
vs
ova
ova
sint
group
signific
differ
achiev
ova
ova
group
group
inhibit
asthma
phenotyp
plo
one
wwwplosoneorg
model
interestingli
knockdown
downregul
experiment
model
thu
lead
improv
ahr
paramet
reduc
specif
ige
product
anoth
novel
find
work
reduct
observ
rhoarhokinas
signal
pathway
silenc
anim
model
allerg
bronchial
asthma
shown
rhoa
mediat
augment
bronchial
smooth
muscl
contractil
one
caus
ahr
recent
rock
involv
regul
allerg
inflamm
fact
rock
inhibitor
test
potenti
treatment
ahr
asthma
moreov
describ
well
augment
bronchial
smooth
muscl
contractil
upregul
rhoa
protein
case
probabl
activ
treatment
reduc
cytokin
thu
control
smooth
muscl
activ
therefor
ahr
known
eosinophil
potenti
sourc
within
asthmat
airway
although
cell
induc
neutrophil
airway
inflamm
also
report
cell
produc
interleukin
also
upregul
cellmedi
eosinophil
airway
inflamm
mice
accord
data
detect
elev
level
asthmat
mice
lung
level
revert
silenc
treatment
time
increas
express
lung
achiev
treat
group
result
clearli
point
modul
regulatori
axi
defici
helper
cell
result
constitut
activ
turn
enhanc
product
model
reduc
phosphoryl
silenc
elev
product
reduc
phosphoryl
probabl
due
abrog
level
complet
way
therapi
focus
reset
natur
regul
process
execut
suppressor
restor
normal
phosphoryl
level
intermedi
case
support
idea
studi
state
local
inhibit
figur
signal
rout
modifi
therapi
total
lung
protein
mice
studi
group
isol
western
blot
analys
perform
measur
rhoa
activ
express
measur
total
protein
densitometr
quantifi
b
rhoa
express
detect
normal
bactin
protein
c
band
densitometri
perform
quantifi
protein
rhoa
e
ss
group
mean
n
ova
group
mean
n
ova
sinttreat
group
mean
n
ova
group
mean
n
group
group
depend
feedback
loop
shown
suppress
experiment
allerg
asthma
major
advantag
use
nake
sirna
simplic
longer
caus
concern
toxic
inflammatori
respons
associ
certain
deliveri
vector
addit
given
intranas
sirna
noninvas
natur
mean
deliv
therapeut
agent
lung
nake
sirna
target
shown
success
inhibit
viral
lung
infect
mous
rhesu
macaqu
fact
human
clinic
trial
current
phase
ii
use
rout
deliv
sirna
treatment
human
rsv
infect
previous
demonstr
eosinophil
one
major
cell
also
observ
correl
bal
eosinophil
express
r
target
airway
massiv
eosinophil
presenc
may
import
mechan
eosinophil
reduct
inhibit
recruit
airway
micrornadriven
rna
interfer
newli
recogn
evolutionari
conserv
regulatori
mechan
use
microarray
analysi
determin
mirna
express
profil
chronic
asthmat
mice
therapi
mirna
modul
transient
knockdown
provid
inform
regul
oper
postranscript
level
moreov
mirna
appear
downregul
therapi
previous
involv
asthma
diseas
would
worthwhil
conduct
studi
mechan
involv
regul
mirna
other
found
use
fluoresc
molecular
tomographi
fmt
obtain
visual
discrimin
measur
quantif
asthma
progress
seen
therapeut
respons
evolv
vivo
quantif
cathepsinactiv
prosens
signal
provid
noninvas
measur
pulmonari
eosinophilia
due
specif
proteas
activ
prosens
eosinophil
moreov
fmt
result
corrobor
convent
invas
techniqu
ex
vivo
measur
addit
xray
comput
tomographi
provid
structur
anatom
lung
inform
chronic
asthma
show
higher
densiti
region
lung
inflammatori
process
take
place
brighter
area
associ
fluid
accumul
reduc
therapi
togeth
new
techniqu
allow
us
noninvas
longitudin
visual
quantifi
inflamm
lung
monitor
therapeut
efficaci
vivo
advantag
therapi
easier
administ
deliv
local
unlik
moriwaki
et
al
studi
downregul
cell
vitro
adopt
transfer
mice
furthermor
cell
eosinophil
cell
airway
probabl
overexpress
therapi
allow
sirna
taken
cell
airway
thu
increas
effect
two
differ
approach
lead
differ
result
thank
local
therapi
sirna
abil
regul
whole
lung
environ
thu
obtain
reduc
level
mrna
turn
increas
express
howev
cell
treatment
sirna
report
moriwaki
et
al
produc
increas
level
bal
fluid
conclus
demonstr
use
differ
vitro
vivo
techniqu
intranas
deliv
chronic
asthma
mous
model
lead
inhibit
asthmat
respons
result
may
hold
therapeut
potenti
asthma
patient
